Streetbeat News

Price Targets

PPG

Analysts have mixed views on PPG Industries (NYSE:PPG), with 3 analysts giving ratings ranging from bullish to somewhat bullish over the last three months. The average 12-month price target for PPG is $159.33, with a high of $166.00 and a low of $152.00. The average target has decreased by 1.65%. Citigroup, Keybanc, and Barclays analysts have recently adjusted their price targets and ratings. PPG is a global coatings producer, with strong financial indicators such as a 3.94% revenue growth rate, a net margin of 9.17%, an ROE of 5.55%, an ROA of 1.95%, and a debt-to-equity ratio of 0.9.

Portfolio Pulse from Benzinga Insights

January 03, 2024 | 5:00 pm

OI

Citigroup has downgraded O-I Glass (NYSE:OI) to Neutral, adjusting the price target from $17.00 to $18.00. Despite the downgrade, the new target suggests a potential upside of 16.13% from the current price of $15.50. O-I Glass is a leading manufacturer of glass bottles, with a significant market presence in Europe, North America, and Brazil, and beer as its primary end market.

Portfolio Pulse from Benzinga Insights

January 03, 2024 | 5:00 pm

CHRD

Mizuho analyst Nitin Kumar has maintained a Buy rating on Chord Energy (NASDAQ:CHRD) but has reduced the price target from $197 to $188.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 4:59 pm

MTDR

Mizuho analyst Nitin Kumar has maintained a Buy rating on Matador Resources (NYSE:MTDR) but has reduced the price target from $83 to $67.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 4:57 pm

SILK

Lake Street analyst Frank Takkinen has initiated coverage on Silk Road Medical (NASDAQ:SILK) with a Buy rating and set a price target of $20.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 4:45 pm

ZBH

Raymond James analyst Jayson Bedford has maintained an Outperform rating on Zimmer Biomet Holdings (NYSE:ZBH) and increased the price target from $133 to $137.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 4:40 pm

JNJ

Raymond James analyst Jayson Bedford has maintained an Outperform rating on Johnson & Johnson (NYSE:JNJ) and increased the price target from $172 to $175.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 4:39 pm

ISRG

Raymond James analyst Jason Bednar has maintained an Outperform rating on Intuitive Surgical (NASDAQ:ISRG) and increased the price target from $310 to $372.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 4:34 pm

DXCM

Raymond James analyst Jayson Bedford has reaffirmed a Strong Buy rating on DexCom (NASDAQ:DXCM) and increased the price target from $131 to $147.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 4:33 pm

BSX

Raymond James analyst Jayson Bedford has reaffirmed a Strong Buy rating on Boston Scientific (NYSE:BSX) and increased the price target from $61 to $67.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 4:27 pm